Initial Medication Management for Severe PAD with a Wound

Introduction to Management

• The American College of Cardiology recommends initiating single antiplatelet therapy with clopidogrel 75 mg daily, high-intensity statin therapy, antihypertensive agents, and aggressive smoking cessation interventions for patients with severe peripheral artery disease and a wound 1, 2

Antiplatelet Therapy

• Clopidogrel 75 mg daily is preferred over aspirin for patients with symptomatic PAD, including those with chronic limb-threatening ischemia, as it reduces the risk of MI, stroke, or vascular death by 23.8% more than aspirin in PAD patients 1, 3, 4, 5
• Aspirin 75-325 mg daily is an acceptable alternative if clopidogrel is not tolerated or available, although its efficacy in PAD is more controversial compared to clopidogrel 1, 3
• Consider adding rivaroxaban 2.5 mg twice daily to aspirin if the patient is not at high bleeding risk, as the COMPASS trial demonstrated a reduction in both major adverse cardiovascular events and major adverse limb events in PAD patients 6, 2
• Dual antiplatelet therapy may be reasonable after lower extremity revascularization to reduce limb-related events, but evidence is limited and bleeding risk is increased 1, 7
• Avoid warfarin or other oral anticoagulants unless there is a separate indication, as anticoagulation does not reduce cardiovascular events in PAD and significantly increases bleeding risk 1, 3, 8

Lipid-Lowering Therapy

• High-intensity statin therapy is mandatory for all PAD patients, with options including atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily, as statins reduce cardiovascular events and mortality in PAD patients 1, 2, 9

Antihypertensive Therapy

• Administer antihypertensive therapy to achieve blood pressure targets in hypertensive PAD patients, with ACE inhibitors or angiotensin receptor blockers preferred for additional cardiovascular protection beyond blood pressure reduction 1

Glycemic Control

• Coordinate glycemic control with the healthcare team, targeting HbA1c <7% when appropriate, as glycemic control is particularly beneficial in CLTI to reduce limb-related outcomes and promote wound healing 1, 7

Smoking Cessation

• Advise the patient to quit at every visit and assist in developing a cessation plan, with prescription of pharmacotherapy such as varenicline, bupropion, and/or nicotine replacement therapy, and referral to a smoking cessation program for additional support 1, 3, 7

Wound Care and Infection Management

• Refer to a multispecialty care team including podiatrists and wound care specialists for advanced wound management, and implement proper foot care and address skin lesions and ulcerations urgently to prevent progression and infection 2, 10, 9, 7
• Manage infection aggressively with appropriate antibiotics and debridement as needed 10, 9

Additional Considerations

• Cilostazol is not appropriate for CLTI, as it is effective for intermittent claudication but not indicated for patients with wounds or CLTI, and is contraindicated in heart failure patients 1
• Avoid homocysteine-lowering therapy, as B-complex vitamin supplementation has no proven benefit for cardiovascular event prevention in PAD 1, 4

Critical Pitfall

• The presence of a wound indicates chronic limb-threatening ischemia, which requires urgent vascular evaluation for revascularization in addition to medical therapy, as medical management alone is insufficient and early recognition and referral to a vascular team are essential for limb salvage 2, 10, 9, 6